Epizyme sets IPO range

Cancer company Epizyme Inc. (Cambridge, Mass.) amended its IPO and said it plans to sell 4.3 million shares at $13-$15. At the $14 mid-point, Epizyme would raise $60 million and be valued at $375 million. Earlier this month, Epizyme said it planned to sell 4.3 million shares in the IPO. Citi; Cowen; Leerink; JMP Securities; and Wedbush PacGrow are underwriters. Epizyme proposed to raise up to $69 million in the offering in April. ...